Gene sequencing refers to the process of determining the nucleotide sequence of deoxyribonucleic acid (DNA) by sequencing equipment to interpret the genetic code of DNA and provide guidance for life science research, clinical diagnosis and treatment. A gene is a functional fragment on a DNA molecule. It is the basic unit of genetic information and the most basic factor that determines all biological species. The gene determines the life and death of a person. It is the cause of health, beauty, and longevity. It is the manipulator and regulator of life. .
Analysis of the global genetic sequencing industry pattern
When developing a sequencer, companies usually design sequencing reagents and consumables. Therefore, the core of the upstream competition in the sequencing industry lies in the competition of the sequencer.
Previously, Illumina accounted for 71% of the global sequencing instrument market; Thermo Fisher took the second place with a 16% market share; Roche ranked third with a market share of 10%. The global market share of the first two sequencer companies is close to 90%, and the genetic sequencer industry has formed an oligopoly.
In the following years, with the continuous upgrading and promotion of the HiSeq series of sequencers, Illumina continued to erode the remaining market share and gradually formed a unique situation. As of 2016, Illumina's market share has grown to 84%.
2016 global next-generation sequencer market competition pattern
In recent years, the gene sequencing market has grown rapidly, from 794 million US dollars in 2007 to 4.5 billion US dollars in 2013, with a compound annual growth rate of 33.5%. It is expected to maintain rapid growth in the next few years, and will continue to grow in 2018. It reached $11.7 billion and the compound annual growth rate was 21.1%.
2007-2018 global gene sequencing industry market size
Analysis of the pattern of China's gene sequencing industry
According to the statistics of the Prospective Industry Research Institute's "Market Prospecting and Investment Strategy Planning Report", Huada Gene is currently the largest gene sequencing center in China, accounting for 20-30% of the market. In 2014, 2015 and 2016, Huada Gene achieved operating income of 1.132 billion yuan, 1.319 billion yuan and 1.711 billion yuan respectively. Based on the revenue of Huada Gene, the size of China's sequencing market in 2017 was approximately It is 6.7 billion yuan and is expected to reach 8 billion yuan in 2018 and 15 billion yuan in 2022.
Market size of China's gene sequencing industry in 2017-2022
China's gene sequencing industry is far from breaking out
According to the data of the Prospective Industry Research Institute, from 2005 to March 2016, China's gene sequencing industry has accumulated 48 investment and financing, and the accumulated investment amount is 220 million US dollars, of which 16 genes were obtained in the 2015 gene sequencing industry. The investment amount is 66.085 million US dollars, the highest value in 11 years. In terms of the number of investment rounds, most of the investment was for the seed angel round and the A round. The total investment of these two types was 31, accounting for 64.6%.
The gene sequencing industry is a huge market space, and the application direction of gene sequencing services is expanding, and the market space will be further expanded.
A tumor is a new organism formed by the body's cells under the action of various carcinogenic factors, and the cells of the local tissue lose control of their growth at the genetic level. According to the 2014 World Cancer Report, global cancer cases are expected to increase from 14 million in 2012 to 19 million in 2025 and 24 million in 2035.
Prospective Industry Research Institute believes that tumor diagnosis and treatment is the most promising application market for gene sequencing. The main reasons are: 1) The global cancer incidence is gradually increasing, and the cancer burden is increasing. One of the 8 death cases is one. It is cancer. Especially for China, the increasing aging of the population, the worsening of environmental pollution and food safety problems, the burden of cancer is particularly prominent. 2) Because of the significant individual differences in tumors, traditional medical methods are used in cancer treatment. There are very large limitations, and gene sequencing can provide information on individual differences in patients and provide guidance for cancer treatment, which can improve the safety and effectiveness of medication.
Permeability Analysis of Global Gene Sequencing Technology in Cancer in 2018
Strong support from national policies
In recent years, as the country accelerates the cultivation of the biotechnology industry, grasps the strategic opportunities of China's new science and technology revolution in the new century, and comprehensively builds an innovative country, the bio-industry is booming, especially the gene sequencing as a national key area, and increased support. Strength, has successively launched a number of policies and systems to support, creating a good policy environment for the development of the industry. In just a few years, China's genetic sequencing has gone through a series of processes from no supervision, to stop, to pilot declaration, and then to the elimination of pilot restrictions. It is one of the industries with the most frequent policy release.
Gene sequencing industry trends
Gene technology will be widely used in research fields such as complex diseases, agricultural genomics, microbiology and metagenomics, and will bring about tremendous changes in human health, agriculture and environmental protection;
The application of genetic technology to reproductive health will significantly reduce birth defects and improve human health;
Tumor genome research will reveal the pathogenesis of tumors, and tumor genome sequencing technology will become the basis for individualized treatment of tumors;
Genomics technology combined with the latest scientific research results of traditional clinical medicine to form precision medicine , revolutionizing disease diagnosis, treatment and clinical decision-making.
Peptides,Human Growth Hormone,Melanotan2,Ghrp
Shaanxi Hongbaiyi Biotech Co., Ltd. , https://www.sxhongbaiyi.com